OBJECTIVES: A novel prostate-specific protein of 94 amino acids (PSP94) promoter/enhancer-directed transgenic murine model of prostate cancer (CaP) was examined to determine the temporal relationship of angiogenesis with the development and progression of CaP. METHODS: Immunohistochemistry and in situ hybridization were performed to determine the protein and mRNA expression of basic fibroblast growth factor, vascular endothelial growth factor, and microvessel formation at different stages of CaP development and progression. RESULTS: Differential expression of basic fibroblast growth factor and vascular endothelial growth factor protein was found with the development and progression of CaP (P <0.0001 and P <0.0001, respectively). Angiogenesis was identified in CaP. mRNA expression of basic fibroblast growth factor and vascular endothelial growth factor was present from high-grade prostatic intraepithelial neoplasia to poorly differentiated CaP. CONCLUSIONS: The PSP94 gene is conserved in humans and rodents; therefore, the PSP94 transgenic murine model of CaP provides a preclinical model to test such antiangiogenic or other chemopreventive therapies that may be predictive of human CaP.
OBJECTIVES: A novel prostate-specific protein of 94 amino acids (PSP94) promoter/enhancer-directed transgenic murine model of prostate cancer (CaP) was examined to determine the temporal relationship of angiogenesis with the development and progression of CaP. METHODS: Immunohistochemistry and in situ hybridization were performed to determine the protein and mRNA expression of basic fibroblast growth factor, vascular endothelial growth factor, and microvessel formation at different stages of CaP development and progression. RESULTS: Differential expression of basic fibroblast growth factor and vascular endothelial growth factor protein was found with the development and progression of CaP (P <0.0001 and P <0.0001, respectively). Angiogenesis was identified in CaP. mRNA expression of basic fibroblast growth factor and vascular endothelial growth factor was present from high-grade prostatic intraepithelial neoplasia to poorly differentiated CaP. CONCLUSIONS: The PSP94 gene is conserved in humans and rodents; therefore, the PSP94 transgenic murine model of CaP provides a preclinical model to test such antiangiogenic or other chemopreventive therapies that may be predictive of human CaP.
Authors: Alejandro Godoy; Viviana P Montecinos; Danny R Gray; Paula Sotomayor; Jeffrey M Yau; R Robert Vethanayagam; Swaroop Singh; James L Mohler; Gary J Smith Journal: Am J Physiol Endocrinol Metab Date: 2010-08-10 Impact factor: 4.310
Authors: Hayley C Whitaker; Zsofia Kote-Jarai; Helen Ross-Adams; Anne Y Warren; Johanna Burge; Anne George; Elizabeth Bancroft; Sameer Jhavar; Daniel Leongamornlert; Malgorzata Tymrakiewicz; Edward Saunders; Elizabeth Page; Anita Mitra; Gillian Mitchell; Geoffrey J Lindeman; D Gareth Evans; Ignacio Blanco; Catherine Mercer; Wendy S Rubinstein; Virginia Clowes; Fiona Douglas; Shirley Hodgson; Lisa Walker; Alan Donaldson; Louise Izatt; Huw Dorkins; Alison Male; Kathy Tucker; Alan Stapleton; Jimmy Lam; Judy Kirk; Hans Lilja; Douglas Easton; Colin Cooper; Rosalind Eeles; David E Neal Journal: PLoS One Date: 2010-10-13 Impact factor: 3.240